Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 juil. 2025 16h29 HE | Source: Robbins LLP

URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate
30 juin 2025 20h34 HE | Source: Robbins LLP

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate
06 juin 2025 18h21 HE | Source: Robbins LLP

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate
30 mai 2025 15h44 HE | Source: Robbins LLP

URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate